Loading clinical trials...
Loading clinical trials...
Browse 1,603 clinical trials for covid-19. Find studies that match your criteria and connect with research centers.
Find trials near:
Showing 181-200 of 1,603 trials
NCT06997653
This study is an open-label and Phase 2b clinical trial of the COVID-19 inactivated TURKOVAC vaccine against SARS-CoV-2 in healthy pregnant women.
NCT05207137
The investigators will randomise individuals from family doctors' lists of patients that are at risk of severe Coronavirus Disease 2019 (COVID-19), and that are not registered as having taken the vaccine against the disease. The patients will be randomised to receiving a phone call from their family physician where the participants are given the opportunity to raise questions they might have around vaccination. The investigators will assess whether this has an impact on vaccine uptake.
NCT05539703
Background Recent studies indicate that a 2nd booster dose is associated with lower risk of severe COVID-19. The studies are based on Israeli registry data, comparing outcomes among individuals who have taken the booster, or not. Interpreting the findings from such non-experimental studies is challenging - there are likely systematic differences between those who accept the offer to take a booster dose, and those who do not. Aim Determine the effect of offering vaccination with a 2nd COVID-19 booster dose on severe COVID-19, measured by hospitalization and death caused by COVID-19. Methods Intervention group: A random sample drawn from the whole population aged 45-64 years with 3 doses of COVID-19 vaccine will receive a personal offer to receive the 4th dose of a COVID-19 vaccine in their municipality. Control group: The rest of the population aged 45-64 with 3 doses, who will receive no such offer. Randomization: The investigators will draw a set of birth dates - can then see who is in the intervention group in Beredt C19 (Norwegian emergency preparedness register for COVID-19) without identifying them individually (personal identification numbers are encrypted). Primary outcome: Hospitalization or death caused by COVID-19 in a period of 10 weeks after invitations are sent. Sample size calculations: 300 000 individuals in the intervention group, assuming risk of the primary outcome is at least 15% lower in the intervention group. (The investigators expect a large proportion NOT to accept the invitation to take the vaccine).